Scaling with Pro10™: a proven, high-yield mammalian suspension technology for producing all serotypes and chimeric forms of rAAV
Discover rAAV-based manufacturing designed to lower risk and accelerate clinical entry
Consistency in gene therapy manufacturing is essential for delivering safe, effective treatments. Yet maintaining uniformity in production processes poses significant challenges, from raw material variability to complex biological systems. This article explores how the biotech industry is adopting new technologies and strategies to enhance consistency across the gene therapy manufacturing lifecycle, ensuring that therapies meet rigorous quality standards from development through commercialization.
Ready to read?
Bayer fully supports coordinated vulnerability disclosure and encourages security researchers who choose to engage in these actions to do so in a responsible manner. Coordinated Vulnerability Disclosure Statement
The rapid advancement of cell and gene therapies offers unprecedented potential to treat complex diseases, but navigating both scientific and financial challenges remains a significant hurdle. From developing robust clinical trials to securing...
In the rapidly evolving field of gene therapy, optimizing the production of adeno-associated viral vectors (AAVs) is essential for success. Our latest white paper dives into the advantages of using transient transfection systems for AAV production,...
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format. Historically, full-empty AAV capsid separation performed using an ultracentrifugation density...
